Tear trough filler, using HA, offers a nonsurgical option for under-eye rejuvenation, requiring precise anatomical knowledge ...

Advanz Pharma and Alvotech announced AVT06, a biosimilar to Eylea, was approved for neovascular age-related macular ...

Alcon showcases new data at APACRS 2025, emphasizing advancements in IOL technology and surgical precision for improved ...

NCX 470 met the primary endpoint of non-inferiority in lowering intraocular pressure (IOP) from baseline compared to the ...

Best disease, or vitelliform macular dystrophy, is a rare, inherited retinal condition causing macular degeneration by ...

VivaVision Biotech welcomes renowned ophthalmologist Quan Dong Nguyen to its scientific advisory board with hopes of boosting ...

RAMQ is a public organization introduced in 1970, following the adoption of the universal health care system in Canada.

The two aim to develop a potential first-in-class melanocortin receptor-targeted treatment for patients with retinal diseases ...

The company previously provided an update in April 2025 stating its intention to lay off approximately 65% of the company ...

Dan Ignaszewski explains how the national advocacy campaign aims to unite patients, researchers, and clinicians to protect ...

Cyte initiates patient dosing in a new trial for famzeretcel, aiming to transform treatment options for retinitis pigmentosa.

Annexin Pharmaceuticals initiates a Phase 2a study for ANXV in diabetic retinopathy to explore new treatment options and ...